Suite 1300
Salt Lake City, UT 84111
Block-1 3rd Floor, Perungudi Bypass Rd, Perungudi,
Chennai - 600096
MGR Main Rd,
Perungudi, Chennai - 600096
Villupuram,
Tamil Nadu – 605602
Oncology Cancer Center Billing for Hospitals
Oncology Revenue Cycle Built for High-Cost, High-Complexity Care
Chemotherapy J-code billing, drug wastage capture, 340B split-billing compliance, infusion charge accuracy, clinical trial segregation, and prior authorization to prevent leakage.
$200B+
US cancer care spending annually
40%+
Oncology claims denial
$500M+
340B savings potential
Why oncology revenue cycle is different?
High-Cost Drug Reimbursement Risk
A single mis-coded J-code in high-volume infusion can drive major revenue loss. With drugs costing thousands per dose, accuracy at unit, route, and NDC level directly determines margin and exposure.
Drug Wastage Revenue Opportunity
Modifier JW, used to bill unused portions of single-dose vials, is consistently undercoded at cancer centers. Accurate wastage capture is both a CMS compliance requirement and a substantial ongoing recovery opportunity.
Prior Authorization at Every Cycle
Most commercial payers and Medicare Advantage plans require PA for each chemotherapy regimen and cycle. High-volume infusion centers face authorization pressure impacting cash flow and access.
340B Compliance Complexity
Split-billing workflows require identification of 340B drugs (JG) and non-340B drugs (TB). Incorrect modifier use creates OIG audit risk, overpayments, and threatens overall 340B financial benefits.
Clinical Trial Billing Segregation
Medicare Coverage Analysis must precede each trial protocol. Errors in routine care vs. research cost segregation create non-payment or False Claims Act risk. Both outcomes are unacceptable and require expertise to prevent.
Continuous Coding Environment
FDA approves new oncology agents continuously. The lag between FDA approval and HCPCS J-code assignment means frequent NOC billing, quarterly code updates, and payer policy changes — requiring oncology expertise.
Where oncology revenue leaks and intervention?
Chemotherapy J-Code & Drug Wastage Billing
Hundreds of oncology drugs carry HCPCS J-codes. Dosage calculation, unit conversion, NDC reporting, route modifiers, and JW wastage billing must be accurate on every claim. Errors at scale drive revenue loss and compliance exposure with no room for approximation.
Prior Authorization at Every Treatment Cycle
Commercial payers and Medicare Advantage plans require PA for each chemotherapy regimen and often each cycle. High-volume infusion centers managing multiple patients face ongoing authorization pressure impacting treatment continuity and cash flow.
340B Split-Billing Compliance
Hospitals with 340B eligibility must maintain separate billing for 340B drugs using JG and non-340B drugs using TB. Incorrect modifier use creates OIG audit risk and overpayments. Accurate 340B billing protects savings and ensures long-term financial performance.
Clinical Trial Billing Segregation
Medicare Coverage Analysis must precede each trial to determine which costs are covered as routine care vs research costs. Incorrect allocation leads to non payment or False Claims Act exposure, a compliance risk for oncology programs. Accurate billing requires expertise.
Radiation Oncology Billing Complexity
IMRT, SBRT, IGRT, proton therapy, and brachytherapy each have distinct CPT billing frameworks with technical and professional components. Simulation, treatment planning, dosimetry, and delivery are billable. Incorrect component billing misrepresents radiation oncology care.
New Drug Coding Lag & NOC Billing
FDA approves new oncology agents continuously. The lag between approval and HCPCS J code assignment means new drugs must be billed as NOC codes J9999 or C9399 with drug name, NDC, dosage, and route documentation, creating payer disputes and delays without expertise.
Enhancing Oncology Model (EOM) Reporting
CMS EOM replaces the Oncology Care Model with enhanced requirements for quality reporting, patient navigation documentation, and care plan compliance. Practices must maintain EOM reporting with FFS claims, adding load without reimbursement if not managed.
High-Value Oncology Revenue Leakage
Oncology revenue leakage occurs across coding, drug billing, authorization, and compliance workflows. Without specialized oversight in J-codes, 340B, clinical trials, and radiation billing, hospitals lose reimbursement and face increased audit and regulatory risk at scale.
Chemo J Code and Wastage
Complete chemotherapy drug billing across HCPCS J codes including dosage calculation, unit conversion, NDC reporting, route modifiers, JW wastage capture, and JZ for no wastage. Includes NOC billing for new agents with name, NDC, documentation.
Oncology Prior Authorization
High volume PA management for chemotherapy regimens including payer workflows, cycle renewal tracking, peer to peer support for denied regimens, and real time authorization tracking by patient, regimen, and payer to prevent delays and denials.
340B Program Billing
Split billing workflows with correct modifier use JG and TB, 340B vs non 340B drug identification at claim, audit documentation for OIG compliance, and quarterly billing accuracy reviews protecting savings.
Infusion Center Administration Billing
Drug administration CPT coding across infusion hierarchy including first hour infusion, additional hours, therapeutic push, and injection with NCCI compliance, payer bundling rules, and audits to identify underbilled infusion encounters.
Radiation Oncology Billing
Technical and professional billing for IMRT, SBRT, IGRT, brachytherapy, and proton therapy including simulation, planning, dosimetry, and delivery codes. Correct TC 26 use, checks, and documentation review ensure full revenue capture.
Clinical Trial Billing Compliance
Medicare Coverage Analysis review, routine care vs research cost segregation, modifier Q0 and Q1 use, and coverage documentation protect oncology programs from denials and False Claims Act exposure. Protocol billing ensures.
Bone Marrow Transplant Billing
High complexity BMT facility and professional billing including preparative regimen coding, transplant procedure billing, and post transplant care with correct DRG assignment, diagnosis sequencing, and coordination with hematology billing types.
Surgical Oncology Billing
Oncology surgical billing with CDI support for cancer DRGs, coordination with anatomic and intraoperative pathology billing, and post surgical follow up coding ensuring complete charge capture and correct classification.
EOM/OCM Reporting Support
Alternative payment model reporting for Enhancing Oncology Model participants including quality metric tracking, care plan compliance, patient navigation reporting, and documentation managed with billing without burden.
Oncology billing dimensions approach
Billing Dimension
Detail & AnnexMed Approach
Claim Form
UB-04 (infusion facility / hospital outpatient); CMS-1500 (medical oncologist professional component)
Drug Billing
HCPCS J codes J0000 J9999 with NDC, units, quarterly updates tracked
Drug Wastage
JW billed for wastage, JZ no wastage, both required for CMS compliance.
NOC Billing
J9999 C9399 used for new drugs with NDC, dosage, route to avoid denials
Administration Codes
CPT 96401 to 96549 infusion hierarchy with NCCI bundling compliance
340B Modifiers
JG for 340B drugs, TB for non 340B, OIG audit documentation maintained
Radiation CPTs
77300 to 77799 technical, 77XX physician codes with TC 26 billing split
Clinical Trial Modifiers
Q0 routine trial service, Q1 non trial service, coverage analysis required
EOM Requirements
EOM needs care plan, navigation, access documentation with FFS billing
Top Denial Types
PA failure, NDC error, JW miss, 340B dispute, trial and infusion errors
Financial outcomes for cancer centers
Drug Reimbursement
Improved high-cost drug reimbursement accuracy through J-code unit precision, NDC compliance, and NOC billing protocols for newly approved agents
Drug Wastage Capture
Retrospective audits identify underbilled JW modifier opportunities; prospective workflows prevent ongoing wastage revenue loss from single-dose vial billing
Infusion Charge Capture
Comprehensive infusion hierarchy coding (CPT 96401–96549) ensures all administration services are captured with correct first-hour and sequential coding across multi-drug regimens
Chemo Denial Reduction
Proactive PA management, payer-specific submission protocols, and cycle renewal tracking reduce chemotherapy denial rates and accelerate reimbursement cycles
340B Program Value
Correct JG TB modifier workflows protect 340B program savings and maintain OIG compliance preserving cost differential between 340B drug acquisition and payer reimbursement
Revenue Integrity
Clinical trial billing compliance and radiation oncology component billing protect against False Claims Act exposure and audit-related revenue recoupment risks and penalties
Why choose us for oncology revenue cycle?
J-Code & Quarterly Update Expertise
Oncology billing team maintains J code expertise through quarterly HCPCS training, ensuring every new drug approval and code change is reflected in billing before first claim submission, protecting reimbursement accuracy on high cost agents from day one.
Drug Wastage Revenue Recovery
AWVs, depression screenings, tobacco counseling, and other separately billable preventive services are identified and billed outside the AIR on every qualifying encounter, recovering revenue most RHCs forfeit by default.
PA Pipeline Management
Our PA management system tracks authorization status by patient, regimen, cycle, and payer, giving oncology administrators real-time visibility into the full PA pipeline and preventing treatment delays caused by authorization failures or cycle renewal gaps.
Proactive 340B Compliance
340B compliance is proactive. Split billing workflows, OIG ready audit documentation, and quarterly reviews keep clients compliant and preserve full financial benefits of program participation efficiently.
Clinical Trial Billing Protection
Clinical trial billing compliance is a dedicated service. Specialists perform Coverage Analysis review, maintain routine vs research cost segregation, and apply Q0 Q1 modifiers to prevent denials and exposure.
EOM Reporting with FFS Billing
Manages Enhancing Oncology Model reporting with fee for service billing, giving oncology programs a single partner for revenue cycle, quality compliance, and alternative payment participation without burden.
Oncology Account Specialists
Dedicated account management by a hospital oncology RCM specialist, not a rotating call center, provides performance oversight, proactive denial analysis, and quarterly integrity reviews from day one of the engagement.
Ready to optimize your oncology revenue cycle?
Discover unrealized cancer center revenue from drug wastage, 340B gaps, and infusion capture issues. Get a customized oncology RCM review from specialists in complex cancer billing.
Trusted by 100+ Healthcare Providers | AAPC, AHIMA & AAHAM Certified | SOC 2 Type II | All 50 States
Case Studies
See the impact we deliver
Discover how AnnexMed reduces denials, accelerates reimbursements, and strengthens financial performance. Backed by measurable outcomes and proven RCM expertise, we deliver operational excellence, revenue stability, and sustainable growth you can trust.
Client Voices
See how our clients succeed
Proven RCM expertise. Delivered at scale.
For over 20 years, AnnexMed has delivered RCM solutions nationwide, combining expert billing, coding, and AR support to drive measurable results and growth.
- 20+ years of proven healthcare RCM experience
- 1,500+ professionals supporting billing, coding & AR
- 500+ certified coders across multiple specialties
- 99%+ compliance with HIPAA and security standards
- All 50 states served with consistent, scalable operations
